() CITIGROUP on May 22 to maintain the Intel Gera’s life science rating as neutral, with the latest target price of $ 28.00.
Intel Gera Life Science released the first quarterly report of the 2024-quarter on May 6. The company’s operating income as of March 31, 2024, with operating income of US $ 369 million, -3.14%year-on-year, a net profit of -32.81 million US dollars.Essence
Integra LifeSciences Holdings Corporation is headquartered in New Jersey Plain. Its medical machinery manufacturing is in the world’s leading position. The company was founded in 1989.Integra LifeSciences Holdings Corporation provides innovative solutions to plastic surgery, neurosurgery, spinal surgery, and reshaping and general surgery.Integra LifeSciences Holdings Corporation is based on a technical platform that uses collagen engineering equipment to repair and regenerate tissue.The company has independently developed a lot of application product production lines, including the regeneration of burns and deep tissue wounds to ductal meningiomy and the repair of tendon.Over the past 20 years, Integla has acquired business with market overlapping customer base and developed products to meet the needs of target customers on the basis of its core regeneration medical technology.Today, Intella has three income categories in surgery, including spine, height reconstruction, and its own brand production lines, neurosurgery and surgical instruments.
